Cargando…

Ventricular Fibrillation after Bortezomib Therapy in a Patient with Systemic Amyloidosis

A 64-year-old female was diagnosed with systemic amyloidosis associated with multiple myeloma. Bortezomib and dexamethasone-therapy was initiated; however, she developed lethal ventricular fibrillation (VF) and cardiac arrest after 84 hours of therapy. Cardiopulmonary resuscitation using direct curr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamasaki, Satoshi, Muta, Tsuyoshi, Higo, Taiki, Kusumoto, Hirotake, Zaitsu, Eiko, Miyamoto, Toshihiro, Oda, Yoshinao, Akashi, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805163/ https://www.ncbi.nlm.nih.gov/pubmed/24179667 http://dx.doi.org/10.4081/hr.2013.e12

Ejemplares similares

Response of Bortezomib Chemotherapy in Hepatic Amyloidosis
por: Hasan, Syed M., et al.
Publicado: (2018)

Efficacy of bortezomib, cyclophosphamide and dexamethasone in cardiac AL amyloidosis
por: Brennan, Xavier, et al.
Publicado: (2022)

Detection of acquired von Willebrand syndrome after ventricular assist device by total thrombus‐formation analysis system
por: Takashio, Seiji, et al.
Publicado: (2020)

A case of AL amyloidosis presenting with refractory ventricular fibrillation
por: Angsubhakorn, Natthapon, et al.
Publicado: (2021)

Cardiac Amyloidosis Responding to Bortezomib: Case Report and Review of Literature
por: Charaf, Edriss, et al.
Publicado: (2009)

Effectiveness of Bortezomib in Cardiac AL Amyloidosis: A Report of Two Cases
por: Nigrelli, Santi, et al.
Publicado: (2014)

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis
por: Fujimoto, Yuki, et al.
Publicado: (2021)

Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib
por: Ravichandran, Sriram, et al.
Publicado: (2021)

First Case of Nodular Localized Primary Cutaneous Amyloidosis Treated With Bortezomib and Dexamethasone
por: Khan, Noman Ahmed Jang, et al.
Publicado: (2021)

Recurrent Syncope and Cardiac Arrest in a Patient with Systemic Light Chain Amyloidosis Treated with Bortezomib
por: Jaipaul, Navin, et al.
Publicado: (2016)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Outcomes of bortezomib combination chemotherapies in autologous stem cell transplantation-ineligible patients with AL amyloidosis
por: Hur, Joon Young, et al.
Publicado: (2021)

Catheter Ablation of Ventricular Tachycardia/Fibrillation in a Patient with Right Ventricular Amyloidosis with Initial Manifestations Mimicking Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy
por: Chung, Fa-Po, et al.
Publicado: (2017)

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
por: Kastritis, E, et al.
Publicado: (2017)

First case of pyrin-associated autoinflammation with neutrophilic dermatosis complicated by amyloidosis
por: Kiyota, Masatomo, et al.
Publicado: (2020)

Safety of Catheter Ablation Therapy for Atrial Fibrillation in Cardiac Amyloidosis
por: Alhassan, Hassan A., et al.
Publicado: (2023)

Light-chain cardiac amyloidosis: a case report of extraordinary sustained pathological response to cyclophosphamide, bortezomib, and dexamethasone combined therapy
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Tyrosine kinase inhibitors induce alternative spliced BCR‐ABL (Ins35bp) variant via inhibition of RNA polymerase II on genomic BCR‐ABL
por: Yuda, Junichiro, et al.
Publicado: (2020)

Pomolidomide for relapsed/refractory light chain amyloidosis after resistance to both bortezomib and daratumumab: A case report
por: Li, Xian, et al.
Publicado: (2022)

Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA
por: Suzuki, Kenshi, et al.
Publicado: (2023)

Radiofrequency catheter ablation of the left ventricular epicardium as an electrophysiological substrate in a patient with idiopathic ventricular fibrillation associated with early repolarization
por: Nakajima, Ikutaro, et al.
Publicado: (2023)

Prognostic value of right ventricular global longitudinal strain in patients with immunoglobulin light-chain cardiac amyloidosis
por: Usuku, Hiroki, et al.
Publicado: (2023)

Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial
por: Minnema, Monique C., et al.
Publicado: (2019)

Left Ventricular Noncompaction with Multiple Thrombi in Apical Aneurysm
por: Yakabe, Daisuke, et al.
Publicado: (2019)

Bortezomib
por: Rajappa, Senthil
Publicado: (2010)

Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation
por: Uchida, Mayako, et al.
Publicado: (2013)

Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations
por: Liu, Jianhao, et al.
Publicado: (2021)

Expansion of NKG2C-expressing Natural Killer Cells after Umbilical Cord Blood Transplantation in a Patient with Peripheral T-cell Lymphoma with Cytotoxic Molecules
por: Muta, Tsuyoshi, et al.
Publicado: (2017)

Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
por: Nuvolone, Mario, et al.
Publicado: (2022)

How to treat atrial fibrillation in patients with cardiac amyloidosis
por: Nomoto, Yu, et al.
Publicado: (2023)

Bortezomib alters sour taste sensitivity in mice
por: Ohishi, Akihiro, et al.
Publicado: (2017)

Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia
por: Sato, Shiho, et al.
Publicado: (2017)

Enforced Granulocyte/Macrophage Colony-stimulating Factor Signals Do Not Support Lymphopoiesis, but Instruct Lymphoid to Myelomonocytic Lineage Conversion
por: Iwasaki-Arai, Junko, et al.
Publicado: (2003)

Emerald Sign for Diagnosing Tracheobronchial Amyloidosis
por: Uchimura, Keigo, et al.
Publicado: (2021)

PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
por: Liu, Yang, et al.
Publicado: (2023)

A feline case of multiple myeloma treated with bortezomib
por: Tani, Hiroyuki, et al.
Publicado: (2022)

Bidirectional Dynamic Change in Shunt Flow Across a Small Ventricular Septal Defect in a Patient With a Left Ventricular Assist Device
por: Sato, Tasuku, et al.
Publicado: (2021)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

Sustained Ventricular Tachycardia as a Harbinger of Cardiac Amyloidosis
por: Oladiran, Oreoluwa, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Therapy: A Boon to Elderly Patients with Advanced Melanoma?
por: Muta, Tsuyoshi
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0qo0vg44cfg0mforoa9ro8st4f